InflaRx (IFRX) AI Stock Analysis

• Market Cap: $79.22M
• Dividend Yield: N/A
• Average Volume (3M): 504.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -1.05
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 411,429
• 30 Day Avg. Volume: 504,147
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1071.71
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.00
• Price Target Upside: 577.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

InflaRx faces significant financial hurdles with ongoing losses and negative cash flows being the main concerns. However, technical indicators show a positive trend, providing some optimism. Valuation metrics highlight profitability issues, while the lack of earnings call insights adds uncertainty. Overall, the stock presents moderate risk with potential upside if financial and operational challenges are addressed.

Positive Factors

Positive Clinical Data

Gohibic demonstrated improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set.

Regulatory Approval

Gohibic receives approval for SARS-CoV-2-induced ARDS in the EU.

Negative Factors

Unmet Clinical Endpoint

Gohibic in the Phase 2b SHINE trial for hidradenitis suppurativa did not meet the primary endpoint.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx (IFRX) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative anti-inflammatory therapeutics by targeting the complement system. The company operates within the biotechnology and pharmaceutical sectors, with its core product being vilobelimab, an anti-C5a monoclonal antibody designed to treat a variety of inflammatory diseases. InflaRx aims to address critical unmet medical needs in conditions such as hidradenitis suppurativa, ANCA-associated vasculitis, and COVID-19 related complications.

How the Company Makes Money

InflaRx generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical companies and research institutions. These arrangements may include milestone payments, upfront payments, and royalties based on the commercial success of its therapeutic candidates. Additionally, InflaRx may receive research grants and funding from government or private organizations to support its development programs. Given that InflaRx is a clinical-stage company, it does not yet have significant revenues from commercialized products, and its financial performance is largely dependent on the progress and success of its clinical trials and regulatory approvals.

InflaRx Financial Statement Overview

Summary

InflaRx's financials indicate significant challenges typical of biotechnology firms, with ongoing losses and negative cash flows. Revenue growth is volatile but shows potential, while the balance sheet remains stable, offering some financial flexibility.

Income Statement

InflaRx shows a minimal revenue base with significant negative profitability metrics. The gross profit margin is negative due to high cost structures relative to revenue. The net profit margin is deeply negative, indicating substantial losses. Revenue growth appears volatile, though recent increases are notable, suggesting some potential in revenue generation. However, EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet indicates a relatively stable equity base with a moderate debt-to-equity ratio, suggesting cautious leverage utilization. Return on equity is negative due to ongoing net losses, impacting shareholder returns. The equity ratio is robust, indicating strong capital structure resilience with significant equity backing total assets.

Cash Flow

Operating cash flows are consistently negative, reflecting operational inefficiencies or high development costs typical in biotechnology. Free cash flow shows a declining trend, although recent cash inflows from financing activities provide some liquidity cushion. The operating cash flow to net income ratio is negative, indicating cash flow challenges in supporting net income deficits.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
166.43K	63.09K	0.00	0.00	0.00	0.00
	Gross Profit
-330.99K	-469.17K	-585.85K	-696.14K	-664.03K	-661.25K
	EBIT
-56.11M	-44.91M	-32.24M	-47.63M	-33.94M	-56.77M
	EBITDA
-60.93M	-42.06M	-31.29M	-46.90M	-32.47M	-56.80M
	Net Income Common Stockholders
-56.53M	-42.67M	-27.04M	-45.65M	-34.01M	-49.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
156.57M	90.27M	81.81M	83.41M	81.13M	115.49M
	Total Assets
159.21M	120.21M	102.40M	125.14M	88.22M	121.58M
	Total Debt
0.00	1.12M	1.36M	1.43M	559.04K	845.95K
	Net Debt
-55.39M	-11.65M	-14.91M	-24.82M	-25.41M	-32.29M
	Total Liabilities
7.82M	17.63M	14.05M	19.86M	10.35M	14.43M
	Stockholders Equity
151.39M	102.67M	88.35M	105.28M	77.86M	107.15M
Cash Flow		Free Cash Flow
-36.78M	-37.89M	-33.91M	-39.97M	-36.62M	-43.80M
	Operating Cash Flow
-47.04M	-37.81M	-33.74M	-39.94M	-36.53M	-43.20M
	Investing Cash Flow
53.55M	-17.70M	19.36M	-25.95M	21.36M	20.34M
	Financing Cash Flow
-385.55K	52.99M	1.94M	61.58M	9.17M	-294.34K

InflaRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 1.18 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 2.12, and below the 200-day MA of 1.78, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 22.69 is Positive, neither overbought nor oversold. The STOCH value of 8.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMGN	75 Outperform	$171.31B	43.30	67.55%	2.79%	18.64%	-39.39%
BIIB	69 Neutral	$21.03B	12.85	10.36%	―	-1.60%	39.71%
VRTX	64 Neutral	$128.40B	―	-3.15%	―	11.64%	-114.72%
RARE	54 Neutral	$3.55B	―	-214.50%	―	29.01%	23.93%
IFRX	52 Neutral	$79.22M	―	-62.38%	―	178.84%	-40.60%
IONS	49 Neutral	$5.25B	―	-93.03%	―	-10.48%	-18.79%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%